4 April 2024
Evgen Pharma
plc
("Evgen",
the "Company" or the "Group")
Result of General
Meeting
and
Total Voting
Rights
Evgen Pharma plc (AIM: EVG), the
clinical stage drug development company developing sulforaphane
based medicines for the treatment of multiple diseases,
announces that at the General Meeting held at 10:00 a.m. at
the offices of Cavendish, One Bartholomew Close, London, EC1A 7BL
on 4 April 2024, the Resolutions proposed were duly passed by way
of a show of hands.
Details of the proxy voting
instructions lodged prior to the General Meeting for each
Resolution are shown on the company's website.
Total Voting Rights
The New Ordinary Shares to be issued
pursuant to the Fundraising are expected to be Admitted to trading
on 5 April 2024. Following Admission of the New Ordinary Shares,
the total number of Ordinary Shares in issue will be 427,346,895,
with no shares held in treasury. This is the figure that may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in the Company under the
FCA's Disclosure Guidance and Transparency Rules.
Unless otherwise defined
herein, terms used in this announcement
have the meaning given to them in the Acquisition, Fundraising and
Change of Name announcement dated 19 March 2024. A further
announcement shall be made regarding the Company's change of name
in due course.
Enquiries
|
Evgen Pharma plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@evgen.com
|
|
Cavendish Capital Markets (NOMAD and
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 20 7220
0500
|
|
Instinctif Partners
Melanie Toyne-Sewell / Jack
Kincade
|
+44 207 457 2020
Evgen@Instinctif.com
|
About Evgen Pharma plc
Evgen Pharma is a clinical stage
drug development company developing sulforaphane based medicines
for the treatment of multiple diseases. The Company's core
technology is Sulforadex®, a method for synthesising and
stabilising the highly biologically active compound sulforaphane
and novel proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is
a patented composition of synthetic sulforaphane and
alpha-cyclodextrin and has undergone clinical trials for
oestrogen-positive (ER+) metastatic breast cancer and recently a
Phase 1b study of the Company's new enteric coated tablet
formulation. The FDA has granted Orphan Drug status to SFX-01 in
malignant glioma. SFX-01 will be investigated initially in this
indication as an investigator sponsored study in the
Netherlands.
The Company also has a wide number
of collaborations with leading academic centres in the UK, Europe
and the US as part of the continuing strategy to build the
scientific data for the compound. Recently, Evgen completed an
out-licensing transaction with Stalicla SA, a Swiss specialist
company in neurodevelopmental disorders, commencing with autism
spectrum disorder. The deal, if successful, will generate milestone
payments of $160.5m and a double-digit royalty on sales.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol EVG.
For further information, please
visit: www.evgen.com.